Synthesis and characterization of a new N4-Schiff base its zinc halide/pseudohalide complexes with thermal, antimicrobial, antioxidant, anticancer, DNA cleavage and wound healing properties Authors: Maryam Rezaee, Morteza Montazerozohori, Reza Naghiha, Esmaeel Panahi Kokhdan, Shima Hosseinifar, Haidar Baghernejad Published: 2026 ABSTRACT AbstractA novel Schiff base ligand, N¹,N²-bis(2-(((1E,2E)-3-(2-methoxyphenyl)allylidene)amino)ethyl)ethane-1,2-diamine (L), was synthesized from triethylenetetramine and o-methoxycinnamaldehyde, and its six new zinc halide/pseudohalide complexes were prepared and characterized using molar conductance measurements, melting point analysis and spectroscopic techniques. Thermogravimetric and differential thermal analyses (TG/DTG/DTA) coupled with the Coats–Redfern method provided key thermo-kinetic activation parameters (A*, E*, ΔH*, ΔG*, ΔS*) for the synthesized complexes. In vitro, zinc(II) complexes with Cl⁻, N₃⁻, and NO₃⁻ exhibited superior antimicrobial activity against Gram-positive (B. subtilis and S. aureus), Gram-negative (E. coli and P. aeruginosa) bacteria, and fungi (C. albicans and A. oryzae) compared to the free ligand. In DPPH and FRAP assays, zinc complexes, especially ZnL(N₃)₂ and ZnLI₂, exhibited superior antioxidant activity compared to the SB-ligand. In the MTT assay, ZnLI₂ and ZnL(NCS)₂ showed the highest anticancer activity against MCF-7 and PC3 cells, respectively. ZnLBr₂, ZnL(NCS)₂, ZnL(NO₃)₂, and ZnL(N₃)₂ completely cleaved E. coli DNA via a non-oxidative hydrolytic mechanism. Finally, the wound-healing potential of the SB-ligand and its ZnLI2 (zinc iodide complex) was evaluated in a rat model of second-degree burns, demonstrating a wound closure percentage of 100% at day 21, which promises its therapeutic efficacy.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-55361-8.Keywords: Schiff bases, Complex, Antimicrobial, Antioxidant, Cytotoxicity, DNA interaction, Burn wound healingSubject terms: Biochemistry, Biotechnology, Cancer, Chemical biology, Chemistry, Drug discovery, Microbiology Introduction Zinc Schiff base complexes (Zn-SB) have emerged as highly promising agents in bioinorganic and medicinal chemistry due to their structural stability, versatile coordination behavior, and broad biomedical potential1,2. Zinc, the second most abundant trace element in mammals, plays a vital role in gene expression, signal transduction, neurotransmission, and exhibits catalytic and enzymatic activities3. Owing to its d10 configuration, zinc ions adopt diverse coordination geometries with coordination numbers ranging from four to six, which underpins their ability to form stable complexes with Schiff base ligands4–6. These complexes demonstrate potent antimicrobial activity against Gram-positive and Gram-negative bacteria as well as pathogenic fungi7–9, while their antioxidant properties enable efficient scavenging of reactive oxygen species (ROS), mitigating oxidative stress and facilitating fibroblast proliferation and extracellular matrix deposition10–12. Furthermore, zinc compounds modulate inflammatory pathways by down-regulatingre pro-inflammatory cytokines such as TNF-α and IL-613,14, thereby establishing a microenvironment conducive to collagen synthesis and tissue remodeling. Mechanistic investigations reveal that these compounds stimulate angiogenesis through VEGF-mediated signaling cascades, improving vascularization and oxygen delivery to injured tissues15,16. Translational research has confirmed that Zn-containing compounds accelerate wound closure, enhance collagen deposition, and sustain zinc release in vivo17–20. Clinical evidence further supports their therapeutic relevance, with systematic reviews and meta-analyses confirming improved healing outcomes in patients with chronic ulcers, burns, and diabetic wounds following zinc supplementation or topical application of zinc-containing biomaterials21–23. The skin, as the largest organ of the body, provides a barrier against pathogens and radiation, while maintaining electrolyte and fluid balance24. Burn injuries, induced by chemicals, radiation, fire, steam, or electricity, result in tissue damage, infection, and excessive inflammation due to toxic mediators, oxidants, and proteases25. The healing of burn wounds involves hemostasis, neovascularization, and re-epithelialization26,27, and recent studies have reported the efficacy of Schiff base ligands and some metal Schiff base complexes in accelerating these processes28–30. Beyond wound healing, Zn-SB complexes exhibit anticancer, antidiabetic, enzyme inhibition, luminescent, and bio-imaging properties31–38, underscoring their multifunctionality in clinical and biomedical science. Collectively, the convergence of preclinical mechanistic insights and emerging clinical data positions Zn-SB complexes as next-generation agents in regenerative medicine, combining antimicrobial protection, oxidative stress modulation, angiogenic stimulation, and matrix remodeling within advanced therapeutic platforms. Although many reports exist on the various metal complexes39,40 with biological and especially the wound healing properties, a comprehensive literature survey reveals that no studies have been conducted on wound healing properties of this type of N4-tetradentate long-chain Schiff base and particularly its metal complexes. Therefore, the present work lies in adding to the literature the biological and especially wound healing properties of these types of compounds. In recent years, our research group has devoted considerable attention to exploring the biological properties of novel Schiff base (SB) compounds41–45. In the present study, we describe the synthesis of a series of tetradentate Zn–SB complexes, obtained via direct reactions of zinc halide/pseudohalide salts with a newly designed SB-ligand, N1,N2-bis(2-(((1E,2E)−3-(2-methoxyphenyl)allylidene)amino) ethyl)ethane-1,2-diamine. The resulting complexes were comprehensively characterized using a combination of physicochemical and spectroscopic techniques. Subsequently, their in vitro biological activities including antimicrobial, antioxidant, anticancer properties, and DNA cleavage potential were systematically evaluated. Moreover, the wound-healing efficacy of the SB-ligand and its zinc iodide complex (ZnLI2) was assessed in the context of second-degree burn injuries. In this research, the hypothesis is that coordination of the new N4-Schiff base ligand to Zn(II) enhances thermal stability and bioactivity. The specific aims were to synthesize and characterize a new ligand and its zinc complexes, and to evaluate their thermal, antioxidant, anticancer, and wound-healing properties. The novelties of this work include a new N₄-Schiff base ligand, its novel zinc complexes, and the first concurrent evaluation of thermal, antioxidant, anticancer, and wound-healing properties in one Zn(II)-Schiff base system, with zinc coordination enhancing all bioactivities (lower IC₅₀, MCF-7/PC3 cytotoxicity, faster wound closure). Experimental Chemicals and apparatus All chemicals were procured from commercial suppliers. The human breast cancer (MCF-7) and human prostate cancer (PC3) cell lines were bought from Pasteur Institute (Tehran, Iran). A JASCO-680 spectrophotometer was employed to record the infrared spectra at a range of 4000–400 cm− 1 using potassium bromide. The Electronic spectra were scanned utilizing a JASCO-570 spectrophotometer in the wavelength region of 200–800 nm in dimethylformamid (4 × 10− 5 M) in quartz cell. The NMR spectra were taken from a Bruker DPX FT/NMR-400 spectrometer, Dimethyl sulfoxide (DMSO-d6) solvent, and tetramethylsilane (TMS) internal standard. Mass spectrometric analysis was conducted using a Sciex 320ab ESI mass spectrometer. Thermal studies (TG/DTG/DTA) of the prepared materials carried out employing Perkin-Elmer Pyris model apparatus from room temperature (RT) to 900 °C under N2 gas atmosphere with a heating rate of 20 °C/min. Melting point/decomposition points and the molar conductivity were measured using KRUSS SPIN Melting Point Meters and Metrohm-712 conductometer apparatuses, respectively. The FE/SEM images were taken from LEO/ZEISS 1455VP and ZEISS Sigma VP models. Synthesis of novel SB-ligand For this, the ethanolic solution of triethylenetetramine was dropwise added to the ethanolic solution of o-methoxycinnamaldehyde. The pale yellow solution was stirred continuously at RT. After 5 h from the progress of the reaction as monitored using TLC technique (solvent: n-hexane: ethylacetate (1:0.2) and Rf=0.5), with reduction of the solvent volume, a viscous oily product was afforded. Several crystallization attempts were carried out using different solvents such as ethanol, methanol, acetonitrile, DCM, chloroform, and even cold n-hexane; however, none successfully produced the ligand in solid form. Consequently, the ligand appears to be viscous oil, as expected for many organic compounds with a long-chain structure. Synthesis of Zn (II) complexes For the synthesis of Zn (II) chelates, fresh SB-ligand ethanolic solution was dropwise added to the corresponding Zn (II) halide/pseudohalide salts ethanolic solution. The solution was then subjected to magnetically stirring for 3 h. The resulting precipitates were isolated and washed with EtOH. After 3 h, no considerable change in efficiency was observed; therefore, this time was selected as optimal. Crystallization of the complexes was attempted using various solvents or solvent mixtures, including CH2Cl2, CH3Cl, CH3CN, CH2Cl2/EtOH, CH2Cl2/MeOH, CH3Cl/EtOH, CH3Cl/MeOH, CH3CN/EtOH, CH3CN/MeOH, CH3CN/Et2O, as well as several other mixtures. However, in all cases, only colored powders of the product were obtained, which were unsuitable for single-crystal X-ray diffraction analysis. Spectral, physical, and analytical data of the prepared materials has been gathered in Tables 1, 2 and 3. Table 1Physical and analytical data of SB-ligand and its respective zinc (II) chelates.CompoundsColorMelting(decomposition)points/CYield, %Elemental analysis (%)Experimental(Calculated)ΛM/Ω−1cm2 mol− 1CH N SB(L)(C26H34N4O2)Yellowoily6771.86)71.24)7.89(7.43)12.89(12.65)1.0ZnLCl2(C26H34Cl2N4O2Zn)Cream259–2617554.70(55.96)6.4(6.71)9.81(9.32)1.16ZnLBr2(C26H34Br2N4O2Zn)Cream207–2104547.33(48.75)5.19(5.84)8.49(8.12)1.32ZnLI2(C26H34I2N4O2Zn)Orange200–2045941.43(42.91)4.55(4.84)7.43(7.15)1.16ZnL(NCS)2(C28H34S2N6O2Zn)Cream148–1526254.58(54.32)6.56(6.23)13.64(13.47)1.49ZnL(N3)2(C26H34N10O2Zn)Orange130–1345753.47(53.21)5.87(5.33)23.98(23.67)1.37ZnL(NO3)2(C26H34N6O8Zn)Orange117–1202950.05(50.75)5.49(5.18)13.47(13.86)1.29ΛM, molar conductivity. Physical and analytical data of SB-ligand and its respective zinc (II) chelates. SB(L) (C26H34N4O2) ZnLCl2 (C26H34Cl2N4O2Zn) ZnLBr2 (C26H34Br2N4O2Zn) ZnLI2 (C26H34I2N4O2Zn) ZnL(NCS)2 (C28H34S2N6O2Zn) ZnL(N3)2 (C26H34N10O2Zn) ZnL(NO3)2 (C26H34N6O8Zn) ΛM, molar conductivity. Table 2Vibrational frequencies (cm− 1) and electronic data (nm) of SB-ligand (L) and its corresponding Zn (II) chelates.CompoundνNHamineνCHalkeneνCHaliph.νCHimineν(NCS/N3/NO3)νC = NνC = CνC-OνM-Nλmax (nm)SB3274304629352830––16311461–14841241––279, 320ZnLCl23228301629272857––16271461–14811249543281, 323ZnLBr23235301229152854––16271457–14771249543282, 325ZnLI23208300429312838––16231457–14811249536285, 330ZnL(NCS)23224300429312838207116231461–14811249539284, 332ZnL(N3)23232300829312842205916231461–14811249536282, 332 ZnL(NO3)232163012293128421342/136916271461 − 14421245590284, 333 Vibrational frequencies (cm− 1) and electronic data (nm) of SB-ligand (L) and its corresponding Zn (II) chelates. Table 3The 1H and 13C NMR spectral data assignments of the SB-ligand and its Zn(II) chelates regarding to Scheme 2.CompoundsProposed assignment of proton and carbonSB(L)1 HNMR13 CNMR8.08 (d, 2Hdd’, J = 8.4 Hz), 7.61 (t, 2Hii’, J1=7.8 Hz, J2 = 6.4 Hz), 7.33 (d, 2Hgg’, J = 7.5 Hz), 7.26 (d, 2Hff’, J = 16.1 Hz), 7.07 (d, 2Hjj’, J = 8.2 Hz), 6.96 (dd, 2Hee’, J1 = 16.1 Hz, J2 = 8.3 Hz), 6.95 (t, 2Hhh’, J1 = 9.0 Hz, J2 = 6.6 Hz), 3.86 (s, 6 H kk’), 3.79 (m, 4Hbb’), 3.10 (bs, 4Haa’), 2.87 (bs, 2HNH), 2.75 (m, 4Hcc’)164.24 (C4,4’), 157.38 (C12,12’), 136.41 (C6,6’), 130.99 (C10,10’), 129.12 (C8,8’), 127.87 (C9,9’), 124.35 (C7,7’), 121.16 (C11,11’), 112.02 (C5,5’), 56.51 (C13,13’), 55.99 (C3,3’), 53.44 (C1,1’), 45.98 (C2,2’)ZnLCl21 HNMR13 CNMR8.36 (d, 2Hdd’, J = 9.1 Hz), 7.56 (d, 2Hgg’, J = 7.7 Hz), 7.52 (d, 2Hff’, J = 16. 0 Hz), 7.44 (dt, 2Hii’, J1=8.1 Hz, J2 = 1.5 Hz), 7.13 (dd, 2Hee’, J1 = 17.0 Hz, J2 = 9.5 Hz), 7.12 (d, 2Hjj’, J = 8.0 Hz), 7.05 (t, 2Hhh’, J = 7.5 Hz), 3.76 (bm, 4Hbb’), 3.01 (bs, 2HNH), 2.91 (bs, 4Haa’), 2.76 (m, 4Hcc’)168.42 (C4,4’), 158.08 (C12,12’), 148.38 (C6,6’), 133.52 (C10,10’), 132.28 (C8,8’), 128.67 (C9,9’), 123.66 (C7,7’), 121.31 (C11,11’), 112.35 (C5,5’), 58.72 (C13,13’), 56.10 (C3,3’), 53.04 (C1,1’), 46.42 (C2,2’)ZnLBr21 HNMR13 CNMR8.38 (d, 2Hdd’, J = 8.9 Hz), 7.56 (d, 2Hgg’, J = 6.6 Hz), 7.53 (d, 2Hff’, J = 15.6 Hz), 7.44 (t, 2Hii’, J = 7.9 Hz), 7.19 (dd, 2Hee’, J1 = 16.0 Hz, J2 = 9.5 Hz), 7.13 (d, 2Hjj’, J = 8.6 Hz), 7.05 (t, 2Hhh’, J = 7.4 Hz), 3.90 (s, 6Hkk’), 3.77 (bs, 4Hbb’), 2.96 (bs, 6Haa’/NH(signals of hydrogens of aa’ and NH have been overlapped), 2.78 (bm, 4Hcc’)169.33 (C4,4’), 158.01 (C12,12’), 148.06 (C6,6’), 132.28 (C10,10’), 131.97 (C8,8’), 128.74 (C9,9’), 123.60 (C7,7’), 121.35 (C11,11’), 112.37 (C5,5’), 58.74 (C13,13’), 56.13 (C3,3’), 53.04 (C1,1’), 47.49 (C2,2’)ZnLI21 HNMR13 CNMR8.36 (d, 2Hdd’, J = 8.6 Hz), 7.57 (d, 2Hgg’, J = 7.1 Hz), 7.49 (d, 2Hff’, J = 16.2 Hz), 7.46 (t, 2Hii’, J1=11.1 Hz, J2 = 7.5 Hz), 7.39 (dd, 2Hee’, J1 = 15.7 Hz, J2 = 7.2 Hz), 7.13 (dt, 2Hhh’, J1 = 8.4 Hz, J2 = 2.7 Hz), 7.05 (d, 2Hjj’, J = 7.7 Hz), 3.75 (bs, 4Hbb’), 3.03 (s, 2HNH), 2.94 (bs, 4Haa’), 2.75 (bm, 4Hcc’)168.78 (C4,4’), 158.06 (C12,12’), 148.39 (C6,6’), 133.52 (C10,10’), 129.59 (C8,8’), 128.68 (C9,9’), 123.66 (C7,7’), 121.30 (C11,11’), 112.42 (C5,5’), 58.22 (C13,13’), 56.27 (C3,3’), 53.15 (C1,1’), 45.14 (C2,2’)ZnL(NCS)21 HNMR13 CNMR8.18 (d, 2Hdd’, J = 8.5 Hz), 7.93 (d, 2Hff’, J = 16.0 Hz), 7.67 (d, 2Hgg’, J = 9.5 Hz), 7.47 (t, 2Hii’, J1=9.2 Hz, J2 = 7.4 Hz), 7.16 (d, 2Hjj’, J = 8.4 Hz), 7.05 (t, 2Hhh’, J1 = 7.4 Hz, J2 = 5.6 Hz), 7.02 (dd, 2Hee’, J1 = 15.7 Hz, J2 = 7.3 Hz), 3.92 (s, 6Hkk’), 3.6 (bs, 4Hbb’), 2.98 (bs, 2HNH), 2.91 (bs, 4Haa’), 2.75 (bm,4Hcc’)169.35 (C4,4’), 156.52 (C12,12’), 148.39 (C6,6’), 135.02 (CSCN), 133.51 (C10,10’), 129.34 (C8,8’), 127.83 (C9,9’), 125.12 (C7,7’), 121.25 (C11,11’), 112.26 (C5,5’), 56.30 (C13,13’), 56.08 (C3,3’), 55.87 (C1,1’), 45.69 (C2,2’)ZnL(N3)21 HNMR13 CNMR8.30 (d, 2Hdd’, J = 8.9 Hz), 7.64 (d, 2Hgg’, J = 6.2 Hz), 7.53 (d, 2Hff’, J = 14.6 Hz), 7.42 (t, 2Hii’, J1=10.4 Hz, J2 = 7.0 Hz), 7.13 (d, 2Hjj’, J1 = 8.4 Hz), 7.03 (t, 2Hhh’, J1 = 10.0 Hz, J2 = 5.5 Hz), 6.96 (dd, 2Hee’, J1 = 15.6 Hz, J2 = 8.3 Hz), 3.89 (s, 6Hkk’), 3.68 (bm, 4Hbb’), 2.87 (bs, 2HNH), 2.74 (bs, 4Haa’)’, 2.68 (bm, 4Hcc’)169.43 (C4,4’), 158.46 (C12,12’), 148.39 (C6,6’), 133.52 (C10,10’), 129.59 (C8,8’), 128.41 (C9,9’), 123.33 (C7,7’), 121.33 (C11,11’), 112.41 (C5,5’), 58.22 (C13,13’), 56.22 (C3,3’), 56.07 (C1,1’), 45.74 (C2,2’)ZnL(NO3)21 HNMR13 CNMR8.62 (d, 2Hdd’, J = 9.5 Hz), 7.92 (d, 2Hff’, J = 16.0 Hz), 7.49 (d, 2Hgg’, J = 6.6 Hz), 7.36 (dd, 2Hii’, J1=12.4 Hz, J2 = 7.5 Hz), 7.16 (d, 2Hjj’, J = 7.9 Hz), 7.07 (t, 2Hhh’, J1 = 8.3 Hz, J2 = 7.3 Hz), 6.87 (dd, 2Hee’, J1 = 16.1 Hz, J2 = 7.8 Hz), 3.83 (s, 6Hkk’), 3.63 (bm, 4Hbb’), 3.08 (bs, 4Haa’), 2.9 (bm, 4Hcc’), 2.76 (s, 2HNH)170.56 (C4,4’), 158.59 (C12,12’), 148.41 (C6,6’), 133.54 (C10,10’), 129.35 (C8,8’), 128.38 (C9,9’), 122.72 (C7,7’), 121.33 (C11,11’), 112.28 (C5,5’), 56.73 (C13,13’), 56.15 (C3,3’), 52.57 (C1,1’), 45.96 (C2,2’) The 1H and 13C NMR spectral data assignments of the SB-ligand and its Zn(II) chelates regarding to Scheme 2. 1 HNMR 13 CNMR 8.08 (d, 2Hdd’, J = 8.4 Hz), 7.61 (t, 2Hii’, J1=7.8 Hz, J2 = 6.4 Hz), 7.33 (d, 2Hgg’, J = 7.5 Hz), 7.26 (d, 2Hff’, J = 16.1 Hz), 7.07 (d, 2Hjj’, J = 8.2 Hz), 6.96 (dd, 2Hee’, J1 = 16.1 Hz, J2 = 8.3 Hz), 6.95 (t, 2Hhh’, J1 = 9.0 Hz, J2 = 6.6 Hz), 3.86 (s, 6 H kk’), 3.79 (m, 4Hbb’), 3.10 (bs, 4Haa’), 2.87 (bs, 2HNH), 2.75 (m, 4Hcc’) 164.24 (C4,4’), 157.38 (C12,12’), 136.41 (C6,6’), 130.99 (C10,10’), 129.12 (C8,8’), 127.87 (C9,9’), 124.35 (C7,7’), 121.16 (C11,11’), 112.02 (C5,5’), 56.51 (C13,13’), 55.99 (C3,3’), 53.44 (C1,1’), 45.98 (C2,2’) 1 HNMR 13 CNMR 8.36 (d, 2Hdd’, J = 9.1 Hz), 7.56 (d, 2Hgg’, J = 7.7 Hz), 7.52 (d, 2Hff’, J = 16. 0 Hz), 7.44 (dt, 2Hii’, J1=8.1 Hz, J2 = 1.5 Hz), 7.13 (dd, 2Hee’, J1 = 17.0 Hz, J2 = 9.5 Hz), 7.12 (d, 2Hjj’, J = 8.0 Hz), 7.05 (t, 2Hhh’, J = 7.5 Hz), 3.76 (bm, 4Hbb’), 3.01 (bs, 2HNH), 2.91 (bs, 4Haa’), 2.76 (m, 4Hcc’) 168.42 (C4,4’), 158.08 (C12,12’), 148.38 (C6,6’), 133.52 (C10,10’), 132.28 (C8,8’), 128.67 (C9,9’), 123.66 (C7,7’), 121.31 (C11,11’), 112.35 (C5,5’), 58.72 (C13,13’), 56.10 (C3,3’), 53.04 (C1,1’), 46.42 (C2,2’) 1 HNMR 13 CNMR 8.38 (d, 2Hdd’, J = 8.9 Hz), 7.56 (d, 2Hgg’, J = 6.6 Hz), 7.53 (d, 2Hff’, J = 15.6 Hz), 7.44 (t, 2Hii’, J = 7.9 Hz), 7.19 (dd, 2Hee’, J1 = 16.0 Hz, J2 = 9.5 Hz), 7.13 (d, 2Hjj’, J = 8.6 Hz), 7.05 (t, 2Hhh’, J = 7.4 Hz), 3.90 (s, 6Hkk’), 3.77 (bs, 4Hbb’), 2.96 (bs, 6Haa’/NH(signals of hydrogens of aa’ and NH have been overlapped), 2.78 (bm, 4Hcc’) 169.33 (C4,4’), 158.01 (C12,12’), 148.06 (C6,6’), 132.28 (C10,10’), 131.97 (C8,8’), 128.74 (C9,9’), 123.60 (C7,7’), 121.35 (C11,11’), 112.37 (C5,5’), 58.74 (C13,13’), 56.13 (C3,3’), 53.04 (C1,1’), 47.49 (C2,2’) 1 HNMR 13 CNMR 8.36 (d, 2Hdd’, J = 8.6 Hz), 7.57 (d, 2Hgg’, J = 7.1 Hz), 7.49 (d, 2Hff’, J = 16.2 Hz), 7.46 (t, 2Hii’, J1=11.1 Hz, J2 = 7.5 Hz), 7.39 (dd, 2Hee’, J1 = 15.7 Hz, J2 = 7.2 Hz), 7.13 (dt, 2Hhh’, J1 = 8.4 Hz, J2 = 2.7 Hz), 7.05 (d, 2Hjj’, J = 7.7 Hz), 3.75 (bs, 4Hbb’), 3.03 (s, 2HNH), 2.94 (bs, 4Haa’), 2.75 (bm, 4Hcc’) 168.78 (C4,4’), 158.06 (C12,12’), 148.39 (C6,6’), 133.52 (C10,10’), 129.59 (C8,8’), 128.68 (C9,9’), 123.66 (C7,7’), 121.30 (C11,11’), 112.42 (C5,5’), 58.22 (C13,13’), 56.27 (C3,3’), 53.15 (C1,1’), 45.14 (C2,2’) 1 HNMR 13 CNMR 8.18 (d, 2Hdd’, J = 8.5 Hz), 7.93 (d, 2Hff’, J = 16.0 Hz), 7.67 (d, 2Hgg’, J = 9.5 Hz), 7.47 (t, 2Hii’, J1=9.2 Hz, J2 = 7.4 Hz), 7.16 (d, 2Hjj’, J = 8.4 Hz), 7.05 (t, 2Hhh’, J1 = 7.4 Hz, J2 = 5.6 Hz), 7.02 (dd, 2Hee’, J1 = 15.7 Hz, J2 = 7.3 Hz), 3.92 (s, 6Hkk’), 3.6 (bs, 4Hbb’), 2.98 (bs, 2HNH), 2.91 (bs, 4Haa’), 2.75 (bm,4Hcc’) 169.35 (C4,4’), 156.52 (C12,12’), 148.39 (C6,6’), 135.02 (CSCN), 133.51 (C10,10’), 129.34 (C8,8’), 127.83 (C9,9’), 125.12 (C7,7’), 121.25 (C11,11’), 112.26 (C5,5’), 56.30 (C13,13’), 56.08 (C3,3’), 55.87 (C1,1’), 45.69 (C2,2’) 1 HNMR 13 CNMR 8.30 (d, 2Hdd’, J = 8.9 Hz), 7.64 (d, 2Hgg’, J = 6.2 Hz), 7.53 (d, 2Hff’, J = 14.6 Hz), 7.42 (t, 2Hii’, J1=10.4 Hz, J2 = 7.0 Hz), 7.13 (d, 2Hjj’, J1 = 8.4 Hz), 7.03 (t, 2Hhh’, J1 = 10.0 Hz, J2 = 5.5 Hz), 6.96 (dd, 2Hee’, J1 = 15.6 Hz, J2 = 8.3 Hz), 3.89 (s, 6Hkk’), 3.68 (bm, 4Hbb’), 2.87 (bs, 2HNH), 2.74 (bs, 4Haa’)’, 2.68 (bm, 4Hcc’) 169.43 (C4,4’), 158.46 (C12,12’), 148.39 (C6,6’), 133.52 (C10,10’), 129.59 (C8,8’), 128.41 (C9,9’), 123.33 (C7,7’), 121.33 (C11,11’), 112.41 (C5,5’), 58.22 (C13,13’), 56.22 (C3,3’), 56.07 (C1,1’), 45.74 (C2,2’) 1 HNMR 13 CNMR 8.62 (d, 2Hdd’, J = 9.5 Hz), 7.92 (d, 2Hff’, J = 16.0 Hz), 7.49 (d, 2Hgg’, J = 6.6 Hz), 7.36 (dd, 2Hii’, J1=12.4 Hz, J2 = 7.5 Hz), 7.16 (d, 2Hjj’, J = 7.9 Hz), 7.07 (t, 2Hhh’, J1 = 8.3 Hz, J2 = 7.3 Hz), 6.87 (dd, 2Hee’, J1 = 16.1 Hz, J2 = 7.8 Hz), 3.83 (s, 6Hkk’), 3.63 (bm, 4Hbb’), 3.08 (bs, 4Haa’), 2.9 (bm, 4Hcc’), 2.76 (s, 2HNH) 170.56 (C4,4’), 158.59 (C12,12’), 148.41 (C6,6’), 133.54 (C10,10’), 129.35 (C8,8’), 128.38 (C9,9’), 122.72 (C7,7’), 121.33 (C11,11’), 112.28 (C5,5’), 56.73 (C13,13’), 56.15 (C3,3’), 52.57 (C1,1’), 45.96 (C2,2’) Biological tests Antimicrobial tests Bioinorganic chemistry provides a foundation for medicinal development; therefore, evaluating the antimicrobial activity of the synthesized compounds is essential. To evaluate the in vitro bactericidal and fungicidal functions, the tested compounds were assessed against several pathogenic microorganisms using the well diffusion method. The tested microorganisms included Gram-positive bacteria (Staphylococcus aureus ATCC: 6538 and Bacillus subtilis ATCC: 6633), Gram-negative bacteria (Pseudomonas aeruginosa ATCC: 9027 and Escherichia coli ATCC: 25922), and fungal pathogens (Aspergillus oryzae and Candida albicans). In the beginning, the solution of the compounds at three diverse concentrations (12.5, 25, and 50 mg/ml in DMSO) was prepared as stock concentrations. Thereafter, 50 µl of each prepared solution were transferred inside created wells in petri dishes including the Muller Hinton Agar (MHA) culture medium (bacterial strains and C. albicans) and Sabouraud Dextrose Agar (SDA) culture medium (A. oryzae) that were inoculated with 100 µl of microbial strains and then incubation of petri dishes carried out overnight at 37 °C (bacterial strains and C. albicans) and in RT for 72 h (A. oryzae). During incubation, the solution of the compound diffuses and affects the growth of the tested microorganisms. At the end, the antimicrobial function of the materials was evaluated by estimating the inhibition zone diameter (IZD) (in mm) around the wells and also as compare to the reference standard drugs like Amoxicillin, Penicillin, and Cephalexin under similar conditions. The controlled trial signifies the antimicrobial inactivity of DMSO solvent against the tested pathogenic microorganisms46. MIC and MBC determination The minimum inhibitory concentration (MIC) is defined as the lowest concentration of an antibacterial agent that inhibits the visible growth of an inoculum after overnight incubation at 37 °C. MIC determination is important in diagnostic laboratories for evaluating the performance of novel antimicrobial agents against resistant pathogenic organisms. MIC values were obtained using a broth serial dilution method with different concentrations of the tested samples. The minimum bactericidal concentration (MBC) is defined as the lowest concentration of an antimicrobial agent that kills more than 99.9% of the bacterial population. MBC values were obtained after overnight incubation of plates containing Mueller Hinton Agar culture medium, which were inoculated with a full loop of the broth solution from MIC tests under aerobic conditions at 37 °C. Morphology of bacterial cells The SEM images resulting from the treatment of B. subtilis and E. coli bacterial cells with the SB-ligand, ZnLBr₂, and ZnLI₂ complexes clearly show their morphological characteristics. In brief, after the fixation of samples (mixture of physiological serum and treated bacteria cells) by %3 glutaraldehyde (GA) in 0.1 M phosphate buffer (pH = 7.3) for 2 h, dehydration was carried out with 30–96% ethanol for 10 min. Finally, the tested compounds were dehydrated in a vacuum oven at 40 °C for 2 h and the morphology of bacterial cells was observable using SEM images. DNA cleavage The DNA interaction of the tested samples was examined using agarose gel electrophoresis, with hydrogen peroxide serving as the oxidant (positive control). The E. coli strain was used as the DNA source, and DNA extraction was performed as previously reported47. Mixtures of each tested sample with DNA (4 µl of 5 mg/ml in DMSO) were incubated for 2 h at 37 °C and then mixed with bromophenol blue dye. These mixtures, along with DNA alone (negative control), the DNA/H₂O₂ mixture (positive control), and a DNA ladder, were loaded into the wells of the agarose gel. Electrophoresis was then run for 30 min at 100 V. After DNA migration was complete, the gel was visualized under ultraviolet light using a transilluminator (Uvitec, England), and images were captured with a camera. The DNA cleavage assay was performed qualitatively. The entire gel was used to run multiple sample series. After electrophoresis, a close-up photograph was taken, focusing only on the lanes corresponding to the tested compounds. Therefore, a full-length gel image with visible edges is not available. This approach is common in descriptive DNA cleavage studies. In vitro antioxidant activity During normal aerobic mechanisms, the body system generates harmful reactive oxygen species (ROS)48. These free radicals are reactive species that can hurt macromolecules like nucleic acids, proteins, and lipids via having unpaired electrons49 and cause heart disease, aging, and cancer50. Antioxidant compounds transfer electrons into reactive free radicals and convert them to unreactive species and therefore destruct of oxidants and scavenging free radicals and minimize oxidative damage48. The evaluation of the antioxidant function of the prepared compounds was done by in vitro DPPH method for measuring free radical scavenging capability and in vitro FRAP method for ascertaining the ferric-reducing antioxidant power. DPPH method DPPH (1,1-Diphenyl-2-picrylhydrazyl) is a stable organic free radical used to quantify the free radical scavenging capacity or hydrogen-donating ability of compounds through oxidative assessment. The DPPH free radical solution appears dark violet and absorbs at 517 nm. Antioxidants reduce DPPH radicals, leading to discoloration of the test solution51. The DPPH assay, as a rapid method, was employed to evaluate the antioxidant capacity of the tested samples in scavenging DPPH free radicals. After preparation of the several concentrations (10, 20, 30, 40, and 50 µg/mL) of the tested compounds and ascorbic acid (standard drug) in different tubes, 1000 µL of DPPH methanolic solution (0.1 mM) was added to them. Then, the tubes were stirred and incubated for 30 min in darkness at RT. The reduction of DPPH solution absorbance at 517 nm (Cecil Instruments Ltd, Milton, UK) and the color developed of the tested solutions patently show the scavenging capability of free radicals by the tested compounds. IC50 (signifies the concentration of the compounds that scavenged 50% of free radicals and is calculated from scavenging activity versus the concentration curve) and AEAC (ascorbic acid equivalent antioxidant capacity) values exhibit the antioxidant ability of the compounds. The data are listed in Table 10. The following formulas were employed for determining the inhibition percentage (%I) of DPPH free radical (IC50) and AEAC2,52: Table 10IC50 values (µg/mL) and effective drug concentration of SB-ligand, ZnLBr2, ZnLI2, and ZnL(NCS)2 against MCF-7 and PC3 cell lines in comparison with cisplatin.Cell typeSBZnLBr2ZnLI2ZnL(NCS)2CisplatinMCF-7106.9582.0568.5387.564.35Effective drug concentration74.8657.4347.9761.923.04PC3109.0782.8982.0577.915.87Effective drug concentration76.3558.0257.4354.544.11 IC50 values (µg/mL) and effective drug concentration of SB-ligand, ZnLBr2, ZnLI2, and ZnL(NCS)2 against MCF-7 and PC3 cell lines in comparison with cisplatin. The absorbance of DPPH free radical (Abs control) and the absorbance of tested compounds (Abs sample) have been measured at 517 nm. FRAP method FRAP (ferric-reducing antioxidant power) is an in vitro technique for determining the antioxidant effect of tested samples. The ferric-reducing antioxidant potential of the samples was assessed based on their ability to reduce ferric ions. Typically, antioxidants act as reducing agents by transferring a single electron53. According to the FRAP method, 1000 µL of working FRAP reagent (300 mmol/L acetate buffer, pH 3.6; 10 mmol/L TPTZ in 40 mmol/L HCl; and 20 mmol/L ferric chloride hexahydrate in a 10:1:1 ratio) was added to 35 µL of the tested compound solution. After 30 min of incubation in darkness at room temperature, the absorbance of the samples was measured using a UV spectrophotometer (Cecil Instruments Ltd, Milton, UK) at 570 nm. Increased absorbance of the tested compounds indicates that they possess ferric ion-reducing potency. The results are presented graphically in Fig. 8. In this method, the FRAP value was calculated against a standard curve of FeSO₄·7 H₂O concentration and expressed as µmol of Fe(III) equivalents per liter. A close-up gel electrophoresis image with a labeled diagram overlaid on it, showing DNA cleavage activity in E. coli by the SB-ligand and its zinc(II) complexes (The close-up photograph without the labeled diagram has been provided as Supplementary Figure S1). Lanes La, Pos, and Neg refer to ladder, DNA alone (as negative control), and the mixture of DNA and H2O2 (as positive control). Lanes A1 to G1 allude to the mixture of DNA with SB- ligand, ZnLCl2, ZnLBr2, ZnLI2, ZnL(NCS)2, ZnL(NO3)2, and ZnL(N3)2, respectively. In vitro cytotoxicity assay In vitro anticancer function of SB-ligand and some its zinc (II) chelates was examined in comparison with cisplatin (positive control) using MTT (3-(4,5-dimethylthiazol-2-yl)−2,5-diphenyltetrazolium bromide) assay against MCF-7 and PC3 cancer cells. The HUVEC (Human umbilical vein endothelial cells) as normal cell lines were employed as control. The seeded cells54 with density of 1 × 104 cells/well in 96-multititre plates were incubated at 37 °C in a 5% carbon dioxide incubator overnight. Then the prepared stock solution by the dissolution of the synthesized compounds in DMSO (0, 50, 75, 100, and 125 µg/mL) that were diluted by culture medium was employed for treating of cancer cells. After incubation overnight, 10 µL (5 mg/mL) of stock MTT solution was added to each well and incubated at 37 °C. After 4 h and with the reduction of MTT produced the purple formazan precipitates. After aspiration of MTT-containing medium, DMSO was added to dissolve formazan. Then, the absorbance of the samples was recorded on a 96-well plate ELISA reader (Bio-Tek Instruments, Winooski, VT, USA) at 570 nm. The IC50 value was described as the tested compound concentration that causes 50% reduction of cellular viability. Nitric oxide (NO) Nitric oxide, a short-lived free radical gas, is synthesized by a family of enzymes called nitric oxide synthases (NOSs) from oxygen (O₂) and L-arginine. This signaling molecule plays a key role in both physiological and pathological processes and has been extensively studied55. The amount of nitrite was used as an indicator of NO generation and was determined by the Griess reaction method56,57. In vivo estimation of the treatment of burn wound Animals Male wistar rats (200–250 g) were procured from the animal house at Yasouj University of Medical Sciences, Yasuj and held at RT (25 ± 2 °C) with 12 h light/dark controlled cycle with the possibility of access to water and food. All animal procedures conducted in this study were meticulously designed, executed, and reported in strict adherence to the fundamental principles and reporting requirements of the ARRIVE guidelines (version 2.0). All experiments were conducted in strict accordance with the approved guidelines for the care and use of laboratory animals based on the “Principles of Laboratory Animal Care” and was approved under the regulations of the Ethics Committee of Yasuj University of Medical Sciences with Approval ID number: IR.YUMS.REC.1402.135). Creation of burn wound Before the burn wound creation, the anesthetization of rats was done with ketamine (10%, 100 mg/kg) (Bremer pharma GMBH 34414 Warburg, Germany). The dorsal neck area of rats was shaved with an electrical hair shaver and in this area; the second-degree burn was created employing a hot object heated to 95 °C for 15 S over a region of approximately 20 mm in diameter. Rats were randomly assigned into groups of 6 and housed individually. Preparation of ointment For the preparation of the applied ointments in this work, we used Eucerin® cream base(Sepidaj Pharmaceutical Company, Iran) as an emulsion base due to its ability in high absorbance of aqueous or oily solutions58. The used ointments were prepared with 25% concentration. Burn wound treatment The rats were divided into 6 groups, each containing 4 rats, as follows: Group I (normal skin) had no burn and no treatment; Group II (negative control group) had a burn without any treatment, and the wound area was washed with distilled water; Group III (positive control group) had burn wounds treated with 25% zinc oxide ointment; Group IV had burn wounds treated with 25% ointment of the Schiff base ligand; Group V had burn wounds treated with 25% ointment of the ZnLI₂ complex; and Group VI had burn wounds treated with 25% ointment of ZnI₂ salt. Treatment began 24 h after burn wound creation, was applied once daily, and continued for 21 days. Estimation of the treatment of burn wound The changes in the burn wound area were observed, and photographed by digital camera at 0, 7, 14, and 21 day after burning and the percentage of wound closure were assessment by Digimizer software (version 4.2.6.0) (https://www.digimizer.com/manual/example-leafs.php) based on the following equation. Where A0 is the initial burn wound site, and At is the burn wound site at the time 7, 14, and 21 day after burning59. Histological analysis For the histological study, the skin tissue samples were collected from the wound areas of each group on the 21 st day post-wounding and their fixation was done in 4% formaldehyde solution. Then samples were dehydrated with graded ethanol, embedded in paraffin, cut into 5 μm thick sections, and stained with Hematoxylin and Eosin (H&E). Finally, the microscopic images of histological changes of samples were recorded by an equipment light microscope (Olympus, Tokyo, Japan) with a camera (Dino Capture, Taiwan, Taipei). SEM analysis of rat skin tissue At 21 days post-injury, the rats were deeply anesthetized with sodium pentobarbital and then sacrificed by cervical dislocation, ensuring minimal distress (AVMA Guidelines 2020). For SEM studies, the skin samples from the dorsal area of wistar rats of each group were excised. The fixation of excised samples was done in cold 2.5% glutaraldehyde and then samples were dehydrated in graded EtOH. Statistical analysis The evaluation of data was done by Graph Pad prism software (version 7) employing One-way ANOVA with subsequent Tukey post-hoc test. The consequences are reported as mean ± standard deviation (SD). P < 0.05 was considered statistically significant. (*P < 0.05, **P < 0.01, and ***P < 0.001 were considered as level of significance, low significance, moderate significance, and highly significant, respectively). Results and discussion Physical properties The novel SB-Ligand (L) and its Zn(II) chelates (ZnLX₂, X = halide/pseudohalide) were synthesized with yields of 29–75%. The low yield (29%) for ZnL(NO₃)₂ is mainly attributed to its poor solubility in the reaction solvent (ethanol/methanol), causing premature precipitation and incorporation of impurities. Additionally, the nitrate anion may act as a weak oxidizing agent, potentially leading to minor ligand degradation. Finally, purification by recrystallization resulted in considerable product loss due to the complex’s low solubility. These colored compounds are stable at room temperature, soluble in DMSO and DMF, but insoluble in ethanol and methanol. Their molar conductivities (1.0–1.49 cm²Ω⁻¹mol⁻¹ at 25 °C in DMF) confirm non-electrolytic behavior, with zinc thiocyanate showing the highest dissociation60. The ligand is oily, while the zinc chelates decompose thermally between 117 and 261 °C without melting. The proposed synthetic processes of the SB-ligand and its Zn (II) chelates are displayed in Scheme 1. The synthesis path of SB-ligand and its zinc (II) complexes. Electronic spectra UV-Vis spectra of the synthesized compounds were scanned in wavelengths range of 200–800 nm in dimethylformamide solution (4 × 10− 5 M) and their absorption data are presented in Fig. 1; Table 2. In the electronic spectrum of SB-ligand, an absorption band at 279 nm assigned to the electronic transition of π→π* of olefinic bond and aromatic rings, and an absorption band at 320 nm belonged to π→π* electronic transitions of C = N chromophores are observed61. Upon complexation, these bands shift to longer wavelengths proving the linkage of SB-ligand to central metal2,46–49. The electronic d→d transitions were no seen in zinc complexes because of d10 electronic configuration of metal ions62. UV–Visible absorption spectra of SB-ligand (L) and its zine (II) chelates. Infra-red spectra FT-IR vibrational frequencies of the compounds were recorded in the range of 4000–400 cm− 1, and some of the characteristic peaks are compiled in Table 2. Representative FT-IR spectra of the SB-ligand, ZnLCl₂, and ZnL(NCS)₂ complexes are shown in Fig. 2. In the FT-IR spectrum of the SB-ligand, the absorption bands at 3285 cm− 1 and 1673 cm− 1, corresponding to the amino (NH₂) groups of triethylenetetramine and the carbonyl (C = O) group of o-methoxycinnamaldehyde, respectively, were not observed, confirming the absence of starting materials and the successful formation of the azomethine group. The vibration frequency of the azomethine group appears at 1631 cm− 1. Upon complexation, it shifts to lower frequencies within the range of 1623–1627 cm− 1 due to weakening of the bond. This weakening results from the donation of lone pair electrons from the imino nitrogen atoms to the Zn(II) ion, which reduces the electron density of the iminic bond, as well as from π-back bonding from the metal d-orbital to the π* orbital of the iminic bond63,64. The frequencey of the C-H bond of iminic group in SB-ligand appeared at 2830 cm− 1. The frequency of the N-H secondary amine groups in SB-ligand spectrum appears at 3274 cm− 1. The shifting of this peak in the complexes spectra clearly shows involving of these amine groups in coordination of SB-ligand to zinc (II) ion. The presence of strong bands at 2059 cm− 1 and 2071 cm− 1 regions of FT/IR spectra of ZnL(N3)2 and ZnL(NCS)2 indicate coordination of N3− and N-NCS− anions to metal center65. Appearance of new weak peaks in the range of 536–590 cm− ascribed to Zn-N bonds in FT/IR spectra of the complexes is another convincing reason for the linkage SB-ligand to zinc (II) ion66. Infrared spectra of SB-ligand, ZnLCl2, and ZnL(NCS)2 complexes. NMR spectra 1H NMR and 13C NMR are other techniques that support well the suggested structures of the prepared compounds based on exhibited labeled structure in scheme 2. The structure of the SB-ligand(L). The alphabetic letters and numbers refer to hydrogen and carbon atoms. Figure 3 depicts the 1H NMR spectra of SB-ligand and ZnLBr2 chelate compound, and the detailed assigned NMR data have been collected in Table 3. In the 1H NMR spectrum of SB-ligand, the characteristic peak of iminic group appears at 8.08 ppm as doublet. In 1H NMR of the complexes, the signals of this iminic group protons are seen in the range of 8.18–8.62 ppm, which indicate linkage of iminic group nitrogens to Zn (II) metal ion. The SB-ligand aromatic protons signals of Hgg’ and Hjj’ as doublet and Hii’ and Hhh’ as triplet are located at 7.33, 7.07, 7.61 and 6.95 ppm, respectively. The SB-ligand olefinic protons signal of Hee’ as doublet of doublet and Hff’ as doublet is seen at 6.96 and 7.26 ppm, respectively. Furthermore, the SB-ligand aliphatic protons signal of Hbb’ and Hcc’ as multiple and Haa’ as broad singlet are appeared at 3.79, 2.75, and 3.10 ppm, respectively. Amine protons signal is observed at 2.87 ppm as broad singlet. The shift of the mentioned signals to up or downfielded regions in 1H NMR spectra of zinc complexes reveals coordination SB-ligand to Zn (II) ion center. In 13C NMR spectrum of SB-ligand, iminic carbon as characteristic signal is located at 164.24 ppm which in zinc complexes are located in the range of 168.42 −170.56 ppm. According to data gathered in Table 3, downfielding or upfielding of carbon signals can well prove coordination of SB-ligand to Zn (II) ion center in the complexes structures. 1H NMR spectra of (a) SB-ligand (L) (b) ZnLBr2 chelate compounds. Mass spectrometry of the zinc complexes Electrospray ionization mass spectra (ESI-MS) (as found in SI) were recorded to confirm the successful synthesis of the zinc complexes. Representative mass spectrum of the ZnLCl₂ complex is shown in Fig. 4. The mass spectra exhibited characteristic peaks at m/z: 570 (M⁺) for ZnLCl₂(M.W.: 570.87), 658 (M⁺−1) for ZnLBr₂ (M.W.: 659.77), 752 (M⁺−1) for ZnLI₂ (M.W.: 753.77), 616 (M⁺) for ZnL(NCS)₂ (M.W.: 616.13), 584 (M⁺) for ZnL(N₃)₂ (M.W.: 584.00), and 622 (M⁺−1) for ZnL(NO₃)₂ (M.W.: 623.97). The observation of these peaks provides strong evidence for the formation of the desired complexes. In addition to these diagnostic signals, peaks at higher m/z values were also observed, which can be attributed to isotopic distributions and/or adduct ions such as [M + Na]⁺, further supporting the authenticity of the complexes. Furthermore, the presence of dominant peaks in the spectra of the zinc complexes indicates the stability of these molecules in the gas phase. Mass spectrum of ZnLCl2. Evaluation of thermal behavior Thermal analysis (TG/DTG/DTA) of the compounds as a function of temperature may suggest the thermal decomposition mechanism of the metal complexes67. SB-ligand was not investigated thermally because of its oily nature. Table 4 is includes the thermal analysis decomposition data of the Zn (II) complexes under nitrogen atmosphere at heating rate of 20 °C min− 1. Thermogravimetric analysis plots of ZnLCl2, ZnLBr2, ZnLI2, ZnL(NCS)2, ZnL(N3)2 and ZnL(NO3)2 complexes are shown in Figures of 5a −5f respectively. Thermal degradation of zinc (II) complexes has occurred during 2–3 steps at the range of 30–890 °C. A suggested thermal decomposition pathway for zinc chloride complex as typical is shown in scheme 3. The results in Table 4 showed that ZnLCl2 and ZnL(N3)2 with 99.59% and 58% of thermal decomposition have minimum and maximum stability among the synthesized complexes, respectively. Moreover, this technique can prove the attendance of water molecules in the compounds via lost weight below 200 °C. Accordingly, the zinc thiocyanate and zinc nitrate complexes are thermally decomposed during 3 steps (Fig. 5d and f) so these compounds lose some water molecules in the first stage and afterward, in the subsequent steps, SB-ligand and anions are lost, and finally metallic zinc leaves out as a final residual. Also, ZnLCl2 complex was thermally decomposed during 3 steps (Fig. 5a). In the first step (251–490 °C), a mass loss of about 28.5% (Calcd. 28.76%) was ascribed to the suggested elimination of C10H12O2 organic portion. In the later step (490–647 °C), suggested segment of C10H8N2 was disrupted from the molecule with a mass loss of about 25.91% (Calcd. 27.36%). In the final step (647–834 °C), the residual fragment equivalent to proposed part of C6H14Cl2N2Zn was departed with a mass loss of about 45.18% (Calcd. 43.79%) of its total mass. Thermal decomposition of ZnLBr2, ZnLI2, and ZnL(N3)2 complexes happened in two steps(Fig. 5b, c and e respectively) with removal of suggested parts as found in Table 4. A final decomposition step, ZnLBr2 and ZnL(N3)2 complexes left out zinc salt but in the case of ZnLI2 complex, zinc metal is suggested as the final residual. Furthermore, the thermo-kinetic activation parameters viz. E* (activation energy), A* (Arrhenius constant), ΔH* (enthalpy), ΔS* (entropy), and ΔG* (Gibbs free energy) were assessed based on TG/DTG plots utilizing Coats-Redfern method for all thermal degradation steps of the complexes68. The calculated results are shown in Table 5. The high and positive activation energy values (22.36–100.44 kJ/mol) imply the thermal stability of all zinc chelates. In all steps of thermal decomposition of the synthesized complexes, the ΔG* (1.99 × 10² – 4.19 × 10² kJ/mol) and ΔH* (15.54–93.06 kJ/mol) values are positive, indicating the nonspontaneous and endothermic nature of the processes, respectively. Additionally, the negative ΔS* values confirm non-normal thermal decomposition of the coordination compounds, similar to many other reports in the literature69. Table 4Thermal analysis information of Zn (II) complexes involving temperature range, mass loss, differential thermal gravimetric (DTG) peak, proposed segment, and final residual.CompoundTemperature range (°C)Mass loss [found(calculated)], %DTG peak (°C)ProposedsegmentFinalresidueZnLCl2251–49028.5(28.76)354.33C10H12O2490–64725.91(27.36)614.12C10H8N2-647–83445.18(43.79)741.74C6H14Cl2N2ZnZnLBr2235–47439.47(40.37)362.13C18H18O20.5ZnBr2474–87336.51(36.44)547.17C8H16BrN4Zn0.5ZnLI2225–43424.25(25.24)365.76C12H14O2Zn434–81569.34(66.09)527.46C14H20I2N4[ZnL(NCS)2]0.0.42H2O32–1751.204101.890.42H2O175–46641.39(40.78)328.57C10H10N2O2S2Zn466–75646.39(47.5)628.73C18H24N4ZnL(N3)2128–68542.67(50.02)286.94C20H20O2Zinc salt685–89015.33(24.31)853.14C6H14N4[ZnL(NO3)2]0.2.18H2O30–1565.91113.622.18H2O156–40638.74(42.06)272.47C18H18O2Zn406–83639.96(46.15)620.17C8H16N6O6 Thermal analysis information of Zn (II) complexes involving temperature range, mass loss, differential thermal gravimetric (DTG) peak, proposed segment, and final residual. The proposed thermal decomposition steps for ZnLCl2 complex. TG/DTG/DTA plots of (a) ZnLCl2, (b) ZnLBr2, (c) ZnLI2, (d) ZnL(NCS)2, (e) ZnL(N3)2, and (f) ZnL(NO3)2 complexes. Table 5Thermo-kinetic parameters of thermal decomposition steps of zinc (II) chelates.CompoundDecompositionstep (°C)E*(kJ/mol)A*(1/S)ΔS*(J/mol·K)ΔH*(kJ/mol)ΔG*(kJ/mol)ZnLCl2251–49068.063.41 × 102−2.66 × 10262.842.3 × 102490–647100.441.96 × 103−2.54 × 10293.063.19 × 102647–83497.689.58 × 101−2.82 × 10289.243.75 × 102ZnLBr2235–47453.145.66−3 × 10247.872.39 × 102474–87322.368.26 × 10− 4−3.76 × 10215.543.24 × 102ZnLI2225–43454.211.06 × 101−2.95 × 10248.892.37 × 102434–81541.592.12 × 10− 2−3.49 × 10234.943.14 × 102[ZnL (NCS)2]0.0.42H2OZnL(N3)232–175-----175–46667.566.39 × 102−2.6 × 10262.562.19 × 102466–75656.733.72 × 10− 1−3.26 × 10249.233.43 × 102128–68529.342.36 × 10− 2−3.45 × 10224.692.18 × 102685–89093.891.44 × 101−2.97 × 10284.534.19 × 102[ZnL (NO3)2]0.2.18H2O30–156--- − − 156–40651.396.48 × 101−2.79 × 10246.851.99 × 102406–83623.298.18 × 10− 4−3.77 × 10215.863.52 × 102 Thermo-kinetic parameters of thermal decomposition steps of zinc (II) chelates. [ZnL (NCS)2]0.0.42H2O ZnL(N3)2 Pharmacological activity Antimicrobial activity For antimicrobial bioassay, bactericidal and fungicidal properties of the synthesized compounds were assessed against some pathogenic organisms from various bacterial strains of G+ (B. subtilis, S. aureus), G− (P. aeruginosa, E. coli) and fungal strains (C. albicans and (A) oryzae). The antimicrobial bioassay investigations were done using three diverse amounts per well (0.625, 1.25 and 2.5 mg/well) by well diffusion method. The resultant data were evaluated as diameter of zone of inhibition (in mm) and as antimicrobial activities of the tested compounds have been listed in Tables 6 and 7 and as column plot are shown in Fig. 6. Zn (II) azide complex presented the best antibacterial activity toward (B) subtilis and P. aeruginosa and the lowest inhibition against E. coli in the mentioned three concentrations. Also, against E. coli and S. aureus, the ZnLCl2 complex had suitable inhibition in every three concentrations. Other complexes exhibited a suitable antimicrobial function against all the used pathogenic strains. In the case of A. oryzae, the highest inhibition is created by ZnL(NO3)2 complex, and the function of other compounds against this fungal strain is ordered as: ZnLCl2 > ZnLI2 ~ ZnLBr2 > ZnL(NCS)2 > ZnL(N3)2 > SB-ligand. Against (C) albicans, zinc halide complexes (ZnLCl2 ~ ZnLI2 > ZnLBr2) were better fungicide than zinc pseudohalide compounds. The different activity of the synthesized compounds toward the tested bacteria strains has been attributed via the impermeability of the microbe cells or the difference in ribosomes of microbial cells. The comparison of the antibacterial function of the tested compounds with standard drugs such as cephalexin, amoxicillin, and penicillin signifies appropriate activity but lower than them against the tested bacteria strains70. The results showed that the bactericidal activity of the zinc chelates is higher than that of the SB-ligand. This finding is also consistent with several recent reports on other types of complexes, such as cobalt and manganese complexes71–73. Zinc ions interact with bacterial enzymes, DNA, and the negatively charged peptidoglycan of the bacterial cell wall, thereby blocking bacterial cell activities such as cell division, replication, and respiration. Eventually, the release of intracellular contents into the environment leads to cell death74. Furthermore, the results indicate that increasing the concentration enhances the antimicrobial activity of the tested compounds. The superior antimicrobial performance of the zinc chloride, zinc azide, and zinc nitrate complexes compared to their zinc bromide, zinc iodide, and zinc thiocyanate counterparts can be rationalized by their physicochemical properties and how these align with known antibacterial and antifungal mechanisms. Chloride, azide, and nitrate are relatively small and high polar and more hydrophilic anions. It seems that their complexes with zinc exhibit higher solubility in studied media, which facilitates diffusion through microbial cell walls and membranes. This property directly supports the mechanism of membrane disruption, a key antibacterial pathway. Furthermore, after penetration, Zn²⁺ ions in the structure of ZnLCl₂, ZnL(N₃)₂, and ZnL(NO₃)₂ due to polarity of zinc-coordinated anion and higher Lewis acidity tend to bind with DNA, bacterial enzymes and etc. destabilize metabolic pathways leading to microorganism death75–77. In contrast, bromide, iodide, and thiocyanate are larger, less polar, and more lipophilic, leading to membrane disruption by their complexes and resulting in weaker penetration into bacterial structures. Moreover, after penetration, azide and nitrate ligands may also provide additional reactivity. Coordinated azide can generate reactive intermediates that damage DNA and proteins. Coordinated nitrate, under certain conditions, can participate in oxidative stress reactions, further destabilizing microbial cells. Bromide, iodide, and thiocyanate, however, are less effective at producing such reactive species, which reduces their antibacterial potency. Ultimately, the number of pathways through which each compound damages microorganisms, together with the extent of the destructive impact exerted by each pathway, determines the relative effectiveness of that compound compared to the others. A similar discussion can be applied to the comparison of antifungal activities. Table 6Bactericidal screening data (zone* of inhibition (mm)) of the compounds at three amounts in mg/well**.Compound concentration(mg/well)BacillussubtilisStaphylococcusaureusPseudomonasaeruginosaEscherichiacoli0.6251.252.50.6251.252.50.6251.252.50.6251.252.5SB(L)12.014.217.14.09.013.013.015.218.09.710.911.5ZnLCl222.027.031.011.21622.112.215.321.115.717.120.0ZnLBr213.717.022.910.012.214.410.016.219.68.0911.7ZnLI214.015.520.011.313.219.211.313.922.17.09.912.6ZnL(NCS)217.423.027.09.512.21514.416.919.89.910.513.6ZnL(N3)222.129.035.09.011.12019.121.328.48.810.213.8ZnL(NO3)222.027.029.013.316.520.110.815.619.29.112.815.0DMSO------------*The reported data correspond to the average of three independent replicates. For this purpose, aliquots of 50 µL from stock solutions with concentrations of 12.5, 25, and 50 mg/mL were subsequently added into the wells, according to the protocol outlined in the experimental section. Bactericidal screening data (zone* of inhibition (mm)) of the compounds at three amounts in mg/well**. *The reported data correspond to the average of three independent replicates. For this purpose, aliquots of 50 µL from stock solutions with concentrations of 12.5, 25, and 50 mg/mL were subsequently added into the wells, according to the protocol outlined in the experimental section. Table 7Antifungal activity of SB-ligand and its zinc (II) chelates as diameter of inhibition zone (mm)*.Compound concentration(mg/well)**Candida albicansAspergillus oryzae12.5255012.52550SB(L)10.213.016.38.114.518.0ZnLCl 210.915.018.2-***19.427.2ZnLBr 211.214.217.1-18.126.1ZnLI 211.313.418.4-19.326.3ZnL(NCS) 211.014.216.2-21.024.4ZnL(N 3 ) 29.312.214.3-17.323.2ZnL(NO 3 ) 212.115.114.2-27.133.0*The reported data correspond to the average of three independent replicates. **For this purpose, aliquots of 50 µL from stock solutions with concentrations of 12.5, 25, and 50 mg/mL were subsequently added into the wells, according to the protocol outlined in the experimental section. *** No zone was observed. Antifungal activity of SB-ligand and its zinc (II) chelates as diameter of inhibition zone (mm)*. *The reported data correspond to the average of three independent replicates. **For this purpose, aliquots of 50 µL from stock solutions with concentrations of 12.5, 25, and 50 mg/mL were subsequently added into the wells, according to the protocol outlined in the experimental section. *** No zone was observed. Effect of SB- ligand and its zinc (II) chelates against different bacterial and fungal strains at 50 mg/mL concentration. To further investigate of the antibacterial effectiveness of the synthesized compounds, determining of MIC and MBC of the compounds against four tested bacterial strains was done. The results in Table 8 displayed that against B. subtilis, the best function belonged to ZnLCl2, ZnLBr2, and ZnL(NO3)2 complexes with MIC and MBC values of 312.5 µg/mL and 625 µg/mL. Against S. aureus, ZnLCl2 complex displayed more effective deterrence than other complexes. ZnL(NCS)2 and ZnL(N3)2 complexes exhibited the least MIC and MBC with values of 156.2 µg/mL and 312.5 µg/mL, respectively, against E. coli. ZnLBr2, ZnL(NCS)2, and ZnL(NO3)2 complexes had the same MIC value of 625 µg/mL against P. aeruginosa. Table 8MIC and MBC data of the compounds for inhibition from the growth in µg/mL.*.CompoundsBacillussubtilisStaphylococcusaureusPseudomonasaeruginosaEscherichiacoliMICMBCMICMBCMICMBCMICMBCSB(L)25005000500010,000500010,00012502500ZnLCl2312.5625312.56251250250012502500ZnLBr2312.562512502500625125012502500ZnLI262512501250250012502500312.5625ZnL(NCS)225005000250050006251250156.2312.5ZnL(N3)262612502500500025005000156.2312.5ZnL(NO3)2312.5625500010,000625125012502500*The reported data correspond to three independent replicates. MIC and MBC data of the compounds for inhibition from the growth in µg/mL.*. *The reported data correspond to three independent replicates. Investigation of morphological changes in bacterial cell wall after treatment The surface morphological changes of the cell wall of treated E. coli and B. subtilis with SB-ligand, ZnLBr2, and ZnLI2 complexes were investigated employing SEM images (Fig. 7). SEM images exhibited that the cell wall of treated bacterial cells of E. coli and B. subtilis by the SB-ligand, ZnLBr2, and ZnLI2 complexes are deformed, damaged, ruptured, and lysed (red circles). These changes are due to the accumulation of the tested samples on the cell membrane, which causes the leakage of cytoplasmic contents into the environment78. According to the figure, in some regions, bacterial cells remained intact. Additionally, the SEM images showed that the zinc bromide and iodide chelates have a greater antibacterial effect than that of the SB-ligand. The SEM images of treated E. coli with (a) SB-ligand, (b) ZnLI2; and treated B. subtilis with (c) SB-ligand, (d) ZnLBr2. Red circles indicate cell membrane damage. Fragmentation of DNA after treatment The efficiency of cleavage of DNA of E. coli as a target by SB-ligand and its zinc (II) chelates was evaluated using electrophoresis. The result has been shown in Fig. 8. Lanes A1 to G1 belong to the blend of DNA with SB-ligand, ZnLCl2, ZnLBr2, ZnLI2, ZnL(NCS)2, ZnL(NO3)2, and ZnL(N3)2, respectively. The lanes La, Pos, and Neg are ascribed to ladder, DNA (DNA alone as negative control), and the mix of H2O2 and DNA (as positive control), respectively. ZnLBr2 (lane C1), ZnL(NCS)2 (lane E1), ZnL(NO3)2 (lane F1), and ZnL(N3)2 (lane G1) complexes completely cleave DNA of E. coli, while ZnLCl2 (lane B1) and ZnLI2 (lane D1) complexes have displayed moderate cleavage and ligand (lane A1) cleaves DNA partially. It is to be noted that Schiff base complexes of zinc represent a unique class of coordination compounds that can promote DNA cleavage through non-oxidative pathways. Unlike transition metal complexes of copper or iron, they do not rely on Fenton-type chemistry. They also do not generate reactive oxygen species (ROS) to induce strand scission. Instead, zinc Schiff base complexes operate via direct coordination and structural perturbation of the DNA double helix. The zinc center, being a Lewis acid, can interact with the phosphate backbone. This enhances the electrophilicity of the phosphor-diester bonds and thereby facilitates hydrolytic cleavage. In addition, Schiff base ligands often possess planar aromatic systems that enable intercalation between DNA base pairs. This increases torsional strain and destabilizes hydrogen bonding within the helix. This dual action (metal coordination and ligand intercalation) creates localized distortions. These distortions render the DNA more susceptible to cleavage even in the absence of oxidative stress. Furthermore, zinc complexes may act as catalytic centers for water activation. They promote nucleophilic attack on the phosphor-diester linkage and accelerate hydrolysis. These mechanisms highlight an important point. DNA cleavage by zinc Schiff base complexes is primarily a consequence of structural and hydrolytic effects. It is not due to radical-mediated oxidation79–81. Such properties have attracted significant interest in medicinal chemistry, as they provide a basis for designing non-oxidative anticancer and antimicrobial agents that minimize collateral oxidative damage to healthy cells. In the current study, it is evident that the investigated compounds cleave DNA into fragments so small that they do not correspond to the molecular weight range typically represented by the ladder bands. Consequently, these fragments are not detectable in the gel electrophoresis image. Antioxidant activity DPPH assay The examination of the antioxidant properties and the free radical quenching function by the synthesized compounds were investigated by DPPH method. The absorbance of the different solutions and DPPH solution (control) was read at 517 nm employing spectrophotometry. IC50 and AEAC (ascorbic acid equivalent antioxidant capacity) values of the tested samples are gathered in Table 9. Although, the resultant antioxidant activity data have shown that ascorbic acid (as standard substance) has more antioxidant activity than that of the tested samples but the activity of the titled compounds is acceptable and pleasant. It was found that Zn (II) complexes have antioxidant properties higher (52.87–144.8 µg/mL) than SB-ligand (159.87 µg/mL) which can be owing to the presence of zinc (II) ion. Among the complexes, ZnL(N3)2 complex exhibited the best activity in scavenging DPPH free radical rather than other complexes with IC50 and AEAC values 52.87 and 743.14 µg/mL, respectively. The function of other compounds in DPPH free radical scavenging is as follows: Table 9IC50 and AEAC (µg/mL) values of ascorbic acid, SB-ligand and its Zn (II) complexes.CompoundsSBZnLCl2ZnLBr2ZnLI2ZnL(NCS)2ZnL(N3)2ZnL(NO3)2AscorbicAcidIC50159.87144.8138.2798.3776.9252.87104.9839.29AEAC245.76271.34284.15399.41510.79743.14374.26-** Ascorbic acid is the reference standard. IC50 and AEAC (µg/mL) values of ascorbic acid, SB-ligand and its Zn (II) complexes. * Ascorbic acid is the reference standard. ZnL(NCS)2 > ZnLI2 > ZnL(NO3)2 > ZnLBr2 > ZnLCl2. The observed trend can be explained by the electronic properties and polarizability of the ligands. Complexes containing azide and thiocyanate exhibit the highest radical scavenging ability due to their strong electron-donating capacity and stabilization of intermediate radical species. In the case of azide, the negative charge is delocalized over three nitrogen atoms through resonance, which enhances electron density and facilitates transfer to the metal center or to radical species. Thiocyanate, on the other hand, is an ambidentate ligand that can coordinate through either nitrogen or sulfur; the sulfur atom is highly polarizable and possesses extended orbitals that readily participate in electron transfer processes. Iodide, with its high polarizability, shows greater activity than bromide and chloride, though less than that of azide and thiocyanate. Nitrate, being electron-withdrawing, reduces electron density and thus displays lower activity. Finally, bromide and chloride, with smaller size and lower polarizability, demonstrate the weakest antioxidant effects. Therefore, differences in electron-donating ability and ligand polarizability are the main factors determining the antioxidant strength of these complexes. FRAP assay FRAP is another method for evaluating the antioxidant function of the tested samples based on conversion of Fe3+-TPTZ to Fe2+-TPTZ. The results as depicted in Fig. 9 show that the ferric-reducing antioxidant power of all the complexes is higher than SB-ligand. Also, ZnLI2 complex displayed the highest antioxidant activity with respect to other complexes, and the activity of other complexes is ordered as ZnL(NCS)2 > ZnLBr2 ~ ZnL(NO3)2 ~ ZnL(N3)2 > ZnLCl2. Ferric reducing-antioxidant power of SB-ligand and its Zn (II) complexes Statistically significant differences are given for the complexes as compared with the SB-ligand (***P < 0.001). Analogous to the rationale provided for the DPPH assay, the observed sequence can be interpreted in terms of the electron-donating capacity and polarizability of the ligands. Nevertheless, because the FRAP method operates through a distinct mechanistic pathway (based on ferric ion reduction rather than radical scavenging), different mechanistic deductions must be considered to explain the variations in antioxidant activity. Iodide, being highly polarizable and an efficient electron donor, provides the strongest reducing capacity, resulting in the highest activity. Thiocyanate also shows significant electron-donating potential due to resonance and its polarizable sulfur atom, placing it next in the series. Bromide, nitrate, and azide exhibit moderate effects: bromide benefits from intermediate polarizability, nitrate is electron-withdrawing, and azide shows delocalized charge but is less effective in direct reduction compared to iodide or thiocyanate. Chloride, with the lowest polarizability and weakest donor ability, demonstrates the least antioxidant activity. A comprehensive overview of the antioxidant activity data reveals some differences between the results obtained using the DPPH and FRAP assays. Differences between the antioxidant results obtained by the DPPH and FRAP assays arise from the distinct mechanisms underlying each method. The DPPH assay measures the ability of compounds to donate hydrogen atoms and directly scavenge free radicals, whereas the FRAP assay evaluates the reducing power of antioxidants by quantifying their capacity to convert Fe³⁺ to Fe²⁺. Consequently, some compounds may exhibit strong radical scavenging activity but relatively weaker reducing ability, or vice versa, leading to variations in the outcomes of the two methods. On the other hand, these differences in final results suggest different mechanisms of action for the two assays. Anticancer activity The relationship between DNA cleavage ability, antioxidant activity, and anticancer properties of a compound is multifaceted. Antioxidants generally protect normal cells by neutralizing reactive oxygen species and preventing oxidative DNA damage, thereby reducing mutagenesis and carcinogenesis. However, in cancer cells, certain compounds can simultaneously exhibit antioxidant capacity and induce DNA cleavage, thereby disrupting genomic integrity and triggering apoptosis. This dual behavior highlights the therapeutic potential of such compounds: they safeguard healthy cells from oxidative stress while selectively exerting cytotoxic effects on malignant cells through DNA damage. Consequently, the interplay between antioxidant and DNA-cleaving activities is considered a critical determinant of anticancer efficacy. Herein, our aim is to investigate the cytotoxicity of representative complexes, and therefore we selected three complexes with comparatively higher antioxidant activity and more DNA cleavage potential for this study. Accordingly, SB-ligand and its ZnLBr2, ZnLI2, and ZnL(NCS)2 chelates were screened for the anticancer activity toward human breast (MCF-7) and human prostate (PC3) cancer cells utilizing MTT assay and the results compared with cisplatin (positive control group) under identical conditions. The cell viability versus concentration of the compounds against two cancer cell lines has been illustrated as Fig. 10. The IC50 values and effective drug concentration (concentration required for 70% cell death) have been compiled in Table 10. Based on the graphs in Fig. 9, the decrease in cell viability depends on the concentration of the synthesized compounds, and with increasing concentration; a significant decrease is seen in cell viability. The concentration range employed was 0, 50, 75, 100, and 125 µg/mL. Concentrations exceeding 125 µg/mL were not assessed, as the IC50 values of all tested compounds presented in Table 10 were below this threshold. Hence, the selected concentration range was specifically designed to enable accurate determination of the IC50 values for the target compounds, rendering higher concentrations unnecessary for evaluating their anticancer activity. Based on IC50 values of the tested compounds against two titled cancer cell lines based on Fig. 9, it was revealed that the tested zinc chelates have higher cytotoxicity than that of SB-ligand, but their activities are lower than cisplatin as referenc in our conditions. ZnLI2 with IC50 of 68.53 µg/mL and ZnL(NCS)2 with IC50 of 77.91 µg/mL exhibited the highest cytotoxicity against MCF-7 and PC3 cell lines, respectively. This superiority of ZnLI2 and ZnL(NCS)2 arises from the higher polarizability and electron-donating ability of iodide and thiocyanate, which enhance cellular uptake, improve interactions with DNA and proteins, and create synergistic effects with zinc. In contrast, bromide provides weaker donor properties and lower bioactivity, resulting in reduced anticancer potential. The Cell viability versus concentration of SB-ligand, ZnLBr2, ZnLI2 and ZnL(NCS)2 against MCF-7(a) PC3 cancer cell lines (b) and; the cell viability of cisplatin as reference against PC3 and MCF-7 cell lines(C) using MTT method. NO assay The amount of NO produced by MCF-7 and PC3 cells treated with synthesized compounds was measured after 24 h of treatment using an enzymatic reaction through the Griess methods. As shown in Fig. 11, the amount of nitric oxide produced by MCF-7 cells treated with SB-ligand, zinc bromide, zinc iodide and zinc thiocyanate complexes were significantly inhibited in the culture medium meanwhile cisplatin increases the metabolites of nitric oxide in the culture medium. Also, the amount of nitric oxide produced by PC3 cells treated with zinc bromide, zinc iodide and zinc thiocyanate complexes were significantly inhibited in the culture medium while the amount of nitric oxide produced by PC3 cells treated with SB-ligand is similar to cisplatin. Zinc iodide complex shows the most effective compound in inhibiting nitric oxide produced by both cancer cells. The differential effect on NO metabolites by zinc complexes as compared with cisplatin may be attributed to distinct mechanisms. Cisplatin is known to induce nitric oxide generation. In contrast, zinc has been shown to scavenge NO and reduce its levels. A proposed mechanism involves the role of zinc in maintaining the structural integrity of NOS enzymes; disruption of the zinc-thiolate cluster leads to reduce NO production82. Effect of the SB-ligand, ZnLBr2, ZnLI2, and ZnL(NCS)2 complexes on produced nitric oxide (NO) level against (a) MCF-7 and (b) PC3 cancer cells. Statistically significant differences are given compared to the control group (**P < 0.01, ***P < 0.001)). In vivo evaluation of burn wound healing effect of zinc iodide complex in rat Although both antioxidant and antimicrobial properties play important roles in burn wound healing, their mechanisms differ significantly. Antioxidants primarily act by reducing oxidative stress, neutralizing free radicals, and minimizing tissue damage, thereby creating a favorable environment for cell proliferation and tissue regeneration. In contrast, antimicrobial agents are essential for preventing and controlling infections, which represent one of the most critical complications in burn injuries. Therefore, combining antioxidant and antimicrobial effects provides synergistic benefits, as antioxidants enhance tissue repair while antimicrobials protect against microbial invasion, ultimately leading to more effective and accelerated wound healing. Among the titled compounds in this study, zinc halide complexes are less expensive than others. Among the zinc halide complexes, although the zinc iodide complex exhibited moderate and, in some cases, comparable antimicrobial activity relative to other ones, its antioxidant activity was found to be superior to that of the other zinc halide complexes. This pronounced antioxidant capacity provided the rationale for its selection in the present investigation, underscoring its potential to contribute novel insights into the burn wound healing application of these zinc-based Schiff base complexes as compared with free SB-ligand, zinc iodide salt and zinc oxide (as known effective compound). Macroscopic aspects The results of the macroscopic evaluation are gathered in Table 11 and shown in Fig. 12. According to the results, the wound healing percentage in all studied groups increased from the 7th to the 21 st day. The healing process progressed uniformly throughout the wound from the periphery to the center and left a scar. So in the group treated with zinc oxide on the 7th day 43.54 ± 5.62, the 14th day 64.09 ± 1.78, and the 21 st day (final day) 100.00 improvement was observed. The wound healing percentage in the group treated with ZnLI2 complex was seen on the 7th day 47.21 ± 6.32, on the 14th day 77.41 ± 3.96, and on the 21 st day 100.00. Also, in the group treated by SB-ligand, improvement was seen on the seventh day 49.87 ± 5.22, the fourteenth day 67.04 ± 6.05, and the twenty-first day 92.12 ± 4.50. According to the results of this research, the highest rate of burn wound healing belonged to the zinc oxide and ZnLI2 complex and in the next degree to SB-ligand. The group treated with zinc iodide salt with incomplete wound treatment did not perform properly in burn wound treatment. Table 11Percentage of burn wound healing in each group during weekly observation.CompoundsWound healing percentage (%)Day 7Day 14Day 21Untreated8.54 ± 5.4327.06 ± 7.6132.61 ± 4.85ZnI29.77 ± 3.0534.78 ± 5.7258.23 ± 6.56SB-ligand49.87 ± 5.2267.04 ± 6.0592.12 ± 4.50ZnLI247.21 ± 6.3277.41 ± 3.96100.00ZnO43.54 ± 5.6264.09 ± 1.78100.00 Percentage of burn wound healing in each group during weekly observation. Effect of the zinc oxide, ZnLI2 complex, SB-ligand, and ZnI2 on the rate of wound closure in burn wounds. It should be noted that the healing of the observed wounds may be related to the antimicrobial effects of the compounds, as it is well known that microbial colonization and biofilm formation in the wound area cause delayed healing and wound-related complications83. The absence of infection at the wound site during the treatment process supports the antimicrobial activity of these compounds, which is consistent with other findings from this research, with results presented in Tables 6 and 7. The antimicrobial properties of the SB-ligand and ZnLI₂ complex improve the rate of the wound healing process and thereby increase the speed of epithelialization. Microscopic aspects The collected tissue sections of normal skin and the untreated group and treated groups with ZnO (standard), ZnI2 salt, ZnLI2 complex, and SB-ligand on the 21 st day post-wounding were compared to each other with histological (Fig. 13) and Field-Emission Scanning Electron Microscopy analyses (Fig. 14). By examining these analyses, the details of the wound areas can be observed and evaluated the therapeutic effect of used different compounds. Histopathological profiles of the burn wounds in wistar rats on the 21 st day (H&E, magnification of × 100). (a) Normal skin (b) untreated group and treated groups with (c) ZnO (standard), (d) ZnI2 salt, (e) ZnLI2 complex (f) ligand (L). D: Dermis, Ep: Epidermis, Hp: Hypoderm, F: Fibroblast, BV: Blood Vessel, HF: Hair Follicle, SG: Sebaceous Glands and M: Muscle. 100 μm. FE/SEM images on the 21 st day post-wounding. (A) Normal skin (B) untreated group and treated groups with (C) ZnO (standard group), (D) ZnI2 salt, (E) ZnLI2 complex (F) ligand (L). Based on the histopathological results (H & E, × 100 magnification) (Fig. 13), regular morphology of epidermis, dermis and hypodermis and also the completed re-epithelialization process were seen in the groups treated with ZnLI2 complex and ligand (L) similar to zinc oxide group (control group). In the groups treated with ZnO, ZnLI2 complex, SB-ligand, and the burn group without treatment (negative control) epidermis was completely mature while in the groups treated with ZnI2 salt this layer was immature and re-epithelialization process was not completed. In the groups treated with ZnLI2 complex and SB-ligand were shown less inflammatory cells, more hair follicles, fibroblasts, sebaceous glands, extensive collagen deposition, and blood vessels rather than the groups treated with ZnI2 salt and the burn group without treatment (negative control). Therefore, the treatment performed with ZnLI2 complex and SB-ligand showed the best re-epithelialization results rather than the group treated with ZnI2 salt and the burn group without treatment. The results of examining the wound healing percentage (Table 11) confirm the above findings. The density and regular arrangement of collagen fibrils and fibers in all treated groups on the 21 st day post-wounding can be observed in the FE/SEM images (Fig. 14). According to the results, among these groups, those treated with ZnO and the ZnLI₂ complex, followed by the group treated with the SB-ligand, exhibit the densest and most regular collagen arrangement, which is comparable to that of normal skin. The SEM images and histological results demonstrate that the two synthesized compounds of the ZnLI₂ complex and the SB-ligand are effective in the treatment of second-degree burn wounds. Overview on the biological properties of studied Schiff base compounds According to the literature84–86, the biological activities of zinc Schiff base complexes arise from the synergistic interplay between the ligand (imine groups and aromatic frameworks enabling interactions with biomolecules) and the zinc ion (stabilizing the coordination environment, enhancing solubility, lipophilicity and cellular uptake)75–77. Although zinc is redox-inert compared to copper or iron, its Lewis acidity and coordination flexibility reinforce biological activity. Importantly, antimicrobial, antioxidant, and anticancer properties are related but not directly proportional, as each involves distinct mechanisms (e.g., membrane disruption, oxidative stress modulation, apoptosis induction) while sharing common pathways such as ROS regulation. In the present study, the highly antimicrobial ZnLCl₂ did not exhibit strong antioxidant activity, whereas ZnLI₂ with moderate antimicrobial activity showed superior antioxidant properties. Furthermore, zinc iodide and thiocyanate complexes, which displayed higher antioxidant activity (DPPH and FRAP assays), also exhibited greater anticancer effects against the tested cancer cell lines. Conclusion In summary, a novel N₄-tetradentate Schiff base ligand (L) and its six zinc(II) halide/pseudohalide complexes were synthesized and characterized. Thermal analysis (TG/DTG/DTA) using the Coats–Redfern method provided key kinetic parameters such as ΔH*, ΔG*, ΔS*. Antimicrobial evaluation against Gram-positive, Gram-negative, and fungal strains revealed that ZnLCl₂, ZnL(N₃)₂, and ZnL(NO₃)₂ exhibited superior activity. Antioxidant assays showed ZnL(N₃)₂ as the best DPPH scavenger (IC₅₀ = 52.87 µg/mL) and ZnLI₂ as the strongest FRAP reducing agent. DNA cleavage studies confirmed that ZnLBr₂, ZnL(NCS)₂, ZnL(NO₃)₂, and ZnL(N₃)₂ completely cleaved E. coli DNA via a non-oxidative hydrolytic mechanism. MTT assays against MCF-7 and PC3 cancer cells demonstrated that ZnLI₂ (IC₅₀ = 68.53 µg/mL) and ZnL(NCS)₂ (IC₅₀ = 77.91 µg/mL) showed the highest anticancer activity. In a second-degree burn wound model, ZnLI₂ achieved 100% wound closure by day 21 with complete re-epithelialization, performing comparably to zinc oxide. Collectively, these zinc complexes particularly ZnLI₂ and ZnL(N₃)₂ exhibit promising multifunctional therapeutic potential for biomedical applications. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements Partial support of this work by Yasouj University is acknowledged. All the experimental procedures in this work were done according to “Principles of Laboratory Animal Care” and the regulations of the animal ethical committee of Yasouj University of Medical Sciences (Code: IR.YUMS.REC.1402.135). Author contributions “M. R and M. M. wrote the main manuscript text. M.M. was supervisor. M.R., R. N., E. P., S. H. and H. B. had roles in biological investigations. All authors reviewed the manuscript.” Data availability The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.